Note 14 - Subsequent Event (Details Textual) - USD ($) |
Aug. 11, 2019 |
Aug. 12, 2019 |
Sep. 27, 2018 |
---|---|---|---|
License Agreement [Member] | Ahon Pharma [Member] | |||
Collaboration Agreement, Non-refundable Payment Payable Upon Regulatory Clearance | $ 4,500,000 | ||
Subsequent Event [Member] | |||
Proceeds from Research and Development Incentives | $ 650,000 | ||
Subsequent Event [Member] | License Agreement [Member] | Ahon Pharma [Member] | |||
Collaboration Agreement, Non-refundable Payment Payable Upon Regulatory Clearance | $ 4,500,000 |
X | ||||||||||
- Definition The amount of non-refundable payment receivable payable upon regulatory clearance in a collaboration agreement. No definition available.
|
X | ||||||||||
- Definition Amount of cash inflow from research and development activities incentives. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|